-
Capricor completes BLA submission to the FDA for the approval of its investigational cell therapy for Duchenne cardiomyopathy
Capricor Therapeutics, which received early funding from CureDuchenne, has completed a Biologics License Application (BLA) […]
-
Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel
PPMD is excited to learn that Capricor Therapeutics has completed the submission of its rolling […]
-
My husband and I make a great team as we care for our sons
Occasionally I struggle to find a topic to write about in my weekly column. I […]
-
Top 10 MD news stories of 2024
During 2024, Muscular Dystrohy News Today covered the latest scientific studies, advances in treatment, and […]
-
New study uncovers key insights into protein interactions in Duchenne muscular dystrophy, paving way for more targeted therapies
A groundbreaking study has shed light on the complex interactions between dystrophin, a protein critical […]
-
Give before midnight TONIGHT to double your impact in developing PPMD’s DCRN
Happy New Year’s Eve! We’re almost there. At midnight we will ring in a new […]
-
Double your impact in advancing the research evolution by the end of 2024
As the clock winds down on 2024 and we prepare to ring in the new […]
-
How my sons’ DMD progression has changed my outlook
In the past 12 months, our oldest daughter got married, our oldest son moved across […]
-
Together, let’s advance the research evolution
For my fellow adults living with Duchenne and Becker, today’s reality is vastly different from […]
-
Even with hearing aids, I still have difficulty in group settings
Facioscapulohumeral muscular dystrophy (FSHD) primarily affects muscles in the face, scapular region, and upper arms, […]
